Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics Plc. (ADAPY)
:ADAPY
ADAPY Stock Chart & Stats
$0.06
-$0.04(-6.19%)
At close: 4:00 PM EST
$0.06
-$0.04(-6.19%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$26.06M
Total Debt (Recent Filing)$48.68M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 05, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)11.47
Price to Sales (P/S)0.76
P/FCF Ratio-1.79
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Asset SaleAdaptimmune has agreed to sell key cell therapies to US WorldMeds for up to $85M, including a $55M upfront payment.
Expansion Of Treatment CentersThe company reported 16 invoiced patients in 2Q, and 30 authorized treatment centers now accepting referrals.
Revenue GrowthTecelra net product revenue for 2Q25 was $11.1M, above consensus estimate and grew ~178% from 1Q25.
Bears Say
Preclinical AssetsThe sale of key assets leaves the company with preclinical assets that are still in the early stages of development.
Stock DowngradeAdaptimmune's stock rating has been downgraded to Neutral from Buy due to the absence of significant near-term opportunities.
Workforce ReductionThe company announced plans to reduce its workforce by 62% as well as the departure of several C-suite executives.
ADAPY FAQ
What was Adaptimmune Therapeutics Plc.’s price range in the past 12 months?
Currently, no data Available
What is Adaptimmune Therapeutics Plc.’s market cap?
Currently, no data Available
When is Adaptimmune Therapeutics Plc.’s upcoming earnings report date?
Adaptimmune Therapeutics Plc.’s upcoming earnings report date is Nov 05, 2025 which is in 5 days.
How were Adaptimmune Therapeutics Plc.’s earnings last quarter?
Adaptimmune Therapeutics Plc. released its earnings results on Aug 13, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.042 by $0.022.
Is Adaptimmune Therapeutics Plc. overvalued?
According to Wall Street analysts Adaptimmune Therapeutics Plc.’s price is currently Overvalued.
Does Adaptimmune Therapeutics Plc. pay dividends?
Adaptimmune Therapeutics Plc. does not currently pay dividends.
What is Adaptimmune Therapeutics Plc.’s EPS estimate?
Adaptimmune Therapeutics Plc.’s EPS estimate is -0.12.
How many shares outstanding does Adaptimmune Therapeutics Plc. have?
Currently, no data Available
What happened to Adaptimmune Therapeutics Plc.’s price movement after its last earnings report?
Adaptimmune Therapeutics Plc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.042. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics Plc.?
Currently, no hedge funds are holding shares in ADAPY
Company Description
Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics plc is a clinical-stage biotechnology company focused on the development of T-cell therapies to treat cancer. Headquartered in Oxford, UK, the company specializes in the field of immunotherapy, particularly utilizing its proprietary T-cell receptor (TCR) technology to engineer T-cells that can target and destroy cancer cells. Adaptimmune is primarily engaged in developing therapies for various cancers, including solid tumors and hematological malignancies, with key products like SPEAR T-cell therapies that are designed to enhance the body’s immune response against cancer.
Technical Analysis
Mersana Therapeutics
―
BioAtla
―
LAVA Therapeutics
―
Senti Biosciences
―
Xilio Therapeutics
―
Ownership Overview
38.27% Insiders
0.13% Mutual Funds
<0.01% Other Institutional Investors
61.59% Public Companies and
Individual Investors